CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/06/26
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/06/26
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerGlobeNewsWire • 10/13/26
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/06/26
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/06/26
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyGlobeNewsWire • 07/27/26
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewsWire • 05/19/26
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive PatientsGlobeNewsWire • 05/15/26
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBCGlobeNewsWire • 05/11/26